Fig. 4

RCC2-YFP expression in tumor cells affects drug sensitivity. a HeLa, CRL5800 and MDA-MA-231 cells expressing YFP or RCC2-YFP were treated with vehicles or increasing doses of Taxol, Nocodazole (Noco), Hydroxyurea (Hydrea), Daunorubicin (Dauno), Cisplatin, Camptothecin (CPT), Staurosporine (STS), 5-Fluorouracil (5-FU) or Irinotecan for 48 h. b, c, d and e Cells were quantitated by a CellTiter-Glo® Luminescent Cell Viability Assay. No significant difference was observed between untreated cells and vehicle-treated cells (0.1% DMSO or 0.1% saline) (b). Surviving cells were calculated as the fraction of vehicle controls (c, d and e). Results were averaged between six wells per dose in two experiments (mean ± S.D.)